Antineoplastic Agents, Alkylating - Pharmacology
Research News and Information

Sunday, November 22, 2009

Interaction of ionizing radiation and ZRBA1, a mixed EGFR/DNA-targeting molecule.

30 Aug 2009 ZRBA1 is a molecule termed 'combi-molecule' designed to induce DNA-alkylating lesions and to block epidermal growth factor receptor (EGFR) tyrosine kinase. Owing to its ability to downregulate the EGFR tyrosine kinase-mediated antiapoptotic ... Read more...

Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis.

24 Aug 2009 Multiple myeloma remains an incurable disease. One of the major problems is that myeloma cells develop drug resistance on interaction with bone marrow stromal cells. In this study, we examined the effects of macrophages (Mvarphis), a type of stromal ... Read more...

IgE, allergy, and risk of glioma: update from the San Francisco Bay Area Adult Glioma Study in the temozolomide era.

30 Jul 2009 The consistently observed inverse relationship of allergic conditions with glioma risk and our previous demonstration that immunoglobulin E (IgE) levels also were lower in glioma patients than controls suggest that atopic allergy may be related to a ... Read more...

Latest indexed articles for 'Antineoplastic Agents, Alkylating - Pharmacology'

These are the very latest articles for this heading:

• Interaction of ionizing radiation and ZRBA1, a mixed EGFR/DNA-targeting molecule. 30 Aug 2009
• Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis. 24 Aug 2009
• IgE, allergy, and risk of glioma: update from the San Francisco Bay Area Adult Glioma Study in the temozolomide era. 30 Jul 2009
• The translesion polymerase Rev3L in the tolerance of alkylating anticancer drugs. 27 Jul 2009
• Prolonged cell cycle response of HeLa cells to low-level alkylation exposure. 26 Jul 2009
• Comment re: Temozolomide preferentially depletes cancer stem cells. 19 Jul 2009
• DNA ligase IV as a new molecular target for temozolomide. 13 Jul 2009
• A sphingosine kinase inhibitor induces cell death in temozolomide resistant glioblastoma cells. 10 Jul 2009
• Zalypsis (PM00104) is a potent inducer of gamma-H2AX foci and reveals the importance of the C ring of trabectedin for transcription-coupled repair inhibition. 5 Jul 2009
• Induction of glutathione-dependent DNA double-strand breaks by the novel anticancer drug brostallicin. 5 Jul 2009
• MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance. 5 Jul 2009
• Selective enrichment of hepatocellular cancer stem cells by chemotherapy. 29 Jun 2009
• The safety of temozolomide in the treatment of malignancies. 29 Jun 2009
• Temozolomide in malignant gliomas: current use and future targets. 17 Jun 2009
• Potent antitumor bifunctional DNA alkylating agents, synthesis and biological activities of 3a-aza-cyclopenta[a]indenes. 14 Jun 2009
• Roles of DNA repair and reductase activity in the cytotoxicity of the hypoxia-activated dinitrobenzamide mustard PR-104A. 7 Jun 2009
• In vivo selection of hematopoietic progenitor cells and temozolomide dose intensification in rhesus macaques through lentiviral transduction with a drug resistance gene. 6 Jun 2009
• Mechanism of thalidomide to enhance cytotoxicity of temozolomide in U251-MG glioma cells in vitro. 3 Jun 2009
• Preclinical efficacy of the bioreductive alkylating agent RH1 against paediatric tumours. 31 May 2009
• Mapping the literature: role of trabectedin as a new chemotherapy option in advanced pretreated soft tissue sarcoma. 30 May 2009

See a longer list of these articles.

Technical information about 'Antineoplastic Agents, Alkylating'

Definition: A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumor efficacy and the presence in their chemical structures of N-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumor cells are not completely understood. (From AMA, Drug Evaluations Annual, 1994, p2026)

Registry Number: 0

Descriptor UI: D018906

Alternative terms: Antineoplastic Agents, Alkylating; Antineoplastic Alkylating Agents; Alkylating Agents, Antineoplastic; Antineoplastic Drugs, Alkylating; Antineoplastics, Alkylating; Alkylating Antineoplastic Drugs; Alkylating Drugs, Antineoplastic; Antineoplastic Alkylating Drugs; Drugs, Antineoplastic Alkylating; Alkylating Antineoplastic Agents; Alkylating Antineoplastics;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Tree Number: D27.505.519.124.035; D27.505.954.248.150; D27.888.569.035.035;

History Note: 96